• Publications
  • Influence

Claim Your Author Page
Ensure your research is discoverable on Semantic Scholar. Claiming your author page allows you to personalize the information displayed and manage your publications. Semantic Scholar automatically creates author pages based on data aggregated from public sources and our publisher partners.
  • Toni K. Choueiri, Ulka N Vaishampayan, +20 authors Ramaprasad Srinivasan
  • Medicine
  • Journal of clinical oncology : official journal…
  • 2013 (First Publication: 10 January 2013)
  • PURPOSE Foretinib is an oral multikinase inhibitor targeting MET, VEGF, RON, AXL, and TIE-2 receptors. Activating mutations or amplifications in MET have been described in patients with papillaryExpand
  • David C Smith, Matthew R Smith, +18 authors Maha Hussain
  • Medicine
  • Journal of clinical oncology : official journal…
  • 2013 (First Publication: 1 February 2013)
  • PURPOSE Cabozantinib (XL184) is an orally bioavailable tyrosine kinase inhibitor with activity against MET and vascular endothelial growth factor receptor 2. We evaluated the activity of cabozantinibExpand
  • Eric Angevin, Jose Antonio López-Martín, +9 authors Bernard Escudier
  • Medicine
  • Clinical Cancer Research
  • 2013 (First Publication: 21 January 2013)
  • Purpose: Signaling through the fibroblast growth factor (FGF) pathway may account for tumor resistance to antiangiogenic therapies targeting the VEGF pathway. Here, dovitinib (TKI258), a potent oralExpand
  • Matthew R Smith, Christopher J. Sweeney, +18 authors Howard I. Scher
  • Medicine
  • Journal of clinical oncology : official journal…
  • 2014 (First Publication: 20 October 2014)
  • PURPOSE Cabozantinib (XL184), an oral inhibitor of multiple receptor tyrosine kinases such as MET and VEGFR2, was evaluated in a phase II nonrandomized expansion study in castration-resistantExpand
  • Eric Angevin, Victor Grünwald, +8 authors Bernard J. Escudier
  • Medicine
  • Journal of clinical oncology : official journal…
  • 2011 (First Publication: 20 May 2011)
  • 4551 Background: Dovitinib is a potent oral inhibitor of angiogenic factors, including the fibroblast growth factor (FGFR) and vascular endothelial growth factor receptors (VEGFR). Phase (ph) I ofExpand
  • M Hussain, Matthew R Smith, +17 authors David C Smith
  • Medicine
  • Journal of clinical oncology : official journal…
  • 2011 (First Publication: 20 May 2011)
  • 4516 Background: Cabozantinib (Cabo) is an inhibitor of MET and VEGFR2. MET signaling promotes tumor growth, invasion and metastasis. METHODS mCRPC patients (pts) with progressive measurableExpand